{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:11:23Z","timestamp":1789726283048,"version":"4.0.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Korea Health Technology R&D Project of the Korea Health Industry Development Institute","award":["HI19C1310"],"award-info":[{"award-number":["HI19C1310"]}]},{"name":"Ministry of Health & Welfare, Republic of Korea","award":["HI22C1518"],"award-info":[{"award-number":["HI22C1518"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The increased risk of hearing loss with macrolides remains controversial. We aimed to systematically review and meta-analyze data on the clinical risk of hearing loss, tinnitus, and ototoxicity following macrolide use. A systematic search was conducted across PubMed, MEDLINE, Cochrane, and Embase databases from database inception to May 2023. Medical Subject Heading (MeSH) terms and text keywords were utilized, without any language restrictions. In addition to the electronic databases, two authors manually and independently searched for relevant studies in the US and European clinical trial registries and Google Scholar. Studies that involved (1) patients who had hearing loss, tinnitus, or ototoxicity after macrolide use, (2) intervention of use of macrolides such as azithromycin, clarithromycin, erythromycin, fidaxomicin, roxithromycin, spiramycin, and\/or telithromycin, (3) comparisons with specified placebos or other antibiotics, (4) outcomes measured as odds ratio (OR), relative risk (RR), hazard ratio (HR), and mean difference for ototoxicity symptoms using randomized control trial (RCT)s and observational studies (case\u2013control, cross-section, and cohort studies) were included. Data extraction was performed independently by two extractors, and a crosscheck was performed to identify any errors. ORs along with their corresponding 95% confidence intervals (CIs) were estimated using random-effects models. The Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guidelines for RCTs and Meta-Analysis of Observational Studies in Epidemiology guidelines for observational studies were followed. We assessed the hearing loss risk after macrolide use versus controls (placebos and other antibiotics). Based on data from 13 studies including 1,142,021 patients (n\u2009=\u2009267,546 for macrolide and n\u2009=\u2009875,089 for controls), the overall pooled OR was 1.25 (95% CI 1.07\u20131.47). In subgroup analysis by study design, the ORs were 1.37 (95% CI 1.08\u20131.73) for RCTs and 1.33 (95% CI 1.24\u20131.43) for case\u2013control studies, indicating that RCT and case\u2013control study designs showed a statistically significant higher risk of hearing loss. The group with underlying diseases such as multiple infectious etiologies (OR, 1.16 [95% CI 0.96\u20131.41]) had a statistically significant lower risk than the group without (OR, 1.53 [95% CI 1.38\u20131.70]\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u2009.013). The findings from this systematic review and meta-analysis suggest that macrolide antibiotics increase the risk of hearing loss and that healthcare professionals should carefully consider this factor while prescribing macrolides.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-50774-1","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T08:02:42Z","timestamp":1704182562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Increased risk of hearing loss associated with macrolide use: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"14","author":[{"given":"Sung Ryul","family":"Shim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YungJin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Min","family":"In","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki\u2010Il","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikhee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoyeon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieun","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Yeup","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"key":"50774_CR1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1542\/peds.2013-2903","volume":"133","author":"LE Vaz","year":"2014","unstructured":"Vaz, L. E. et al. Recent trends in outpatient antibiotic use in children. Pediatrics 133, 375\u2013385 (2014).","journal-title":"Pediatrics"},{"key":"50774_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1542\/peds.2008-2869","volume":"124","author":"L Vernacchio","year":"2009","unstructured":"Vernacchio, L., Kelly, J. P., Kaufman, D. W. & Mitchell, A. A. Medication use among children <12 years of age in the United States: Results from the Slone Survey. Pediatrics 124, 446\u2013454 (2009).","journal-title":"Pediatrics"},{"key":"50774_CR3","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1542\/peds.2004-0311","volume":"114","author":"CJ Stille","year":"2004","unstructured":"Stille, C. J. et al. Increased use of second-generation macrolide antibiotics for children in nine health plans in the United States. Pediatrics 114, 1206\u20131211 (2004).","journal-title":"Pediatrics"},{"key":"50774_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0140-6736(94)91030-8","volume":"343","author":"MR Wallace","year":"1994","unstructured":"Wallace, M. R., Miller, L. K., Nguyen, M. T. & Shields, A. R. Ototoxicity with azithromycin. Lancet 343, 241 (1994).","journal-title":"Lancet"},{"key":"50774_CR5","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1001\/archinte.1993.00410070063009","volume":"153","author":"EM Vasquez","year":"1993","unstructured":"Vasquez, E. M., Maddux, M. S., Sanchez, J. & Pollak, R. Clinically significant hearing loss in renal allograft recipients treated with intravenous erythromycin. Arch. Intern. Med. 153, 879\u2013882 (1993).","journal-title":"Arch. Intern. Med."},{"key":"50774_CR6","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1177\/106002809302700724","volume":"27","author":"JA Sacristan","year":"1993","unstructured":"Sacristan, J. A., Soto, J. A. & de Cos, M. A. Erythromycin-induced hypoacusis: 11 new cases and literature review. Ann. Pharmacother. 27, 950\u2013955 (1993).","journal-title":"Ann. Pharmacother."},{"key":"50774_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0002-9343(92)90016-5","volume":"92","author":"DJ Swanson","year":"1992","unstructured":"Swanson, D. J. et al. Erythromycin ototoxicity: Prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am. J. Med. 92, 61\u201368 (1992).","journal-title":"Am. J. Med."},{"key":"50774_CR8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/019459988409200615","volume":"92","author":"RC Haydon","year":"1984","unstructured":"Haydon, R. C., Thelin, J. W. & Davis, W. E. Erythromycin ototoxicity: Analysis and conclusions based on 22 case reports. Otolaryngol. Head Neck Surg. 92, 678\u2013684 (1984).","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"50774_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/000348947708600103","volume":"86","author":"CS Karmody","year":"1977","unstructured":"Karmody, C. S. & Weinstein, L. Reversible sensorineural hearing loss with intravenous erythromycin lactobionate. Ann. Otol. Rhinol. Laryngol. 86, 9\u201311 (1977).","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"50774_CR10","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jama.2013.1937","volume":"309","author":"J Altenburg","year":"2013","unstructured":"Altenburg, J. et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: The BAT randomized controlled trial. JAMA 309, 1251\u20131259 (2013).","journal-title":"JAMA"},{"key":"50774_CR11","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3122\/jabfm.2012.04.110309","volume":"25","author":"DL Hahn","year":"2012","unstructured":"Hahn, D. L., Grasmick, M., Hetzel, S. & Yale, S. Azithromycin for bronchial asthma in adults: An effectiveness trial. J. Am. Board Fam. Med. 25, 442\u2013459 (2012).","journal-title":"J. Am. Board Fam. Med."},{"key":"50774_CR12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMoa1104623","volume":"365","author":"RK Albert","year":"2011","unstructured":"Albert, R. K. et al. Azithromycin for prevention of exacerbations of COPD. Article. N. Engl. J. Med. 365, 689\u2013698 (2011).","journal-title":"Article. N. Engl. J. Med."},{"key":"50774_CR13","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa043526","volume":"352","author":"JT Grayston","year":"2005","unstructured":"Grayston, J. T. et al. Azithromycin for the secondary prevention of coronary events. N. Engl. J. Med. 352, 1637\u20131645 (2005).","journal-title":"N. Engl. J. Med."},{"key":"50774_CR14","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1128\/AAC.47.7.2199-2203.2003","volume":"47","author":"WR Taylor","year":"2003","unstructured":"Taylor, W. R. et al. Tolerability of azithromycin as malaria prophylaxis in adults in northeast Papua, Indonesia. Antimicrob. Agents Chemother. 47, 2199\u20132203 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"50774_CR15","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","volume":"290","author":"L Saiman","year":"2023","unstructured":"Saiman, L. et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA 290, 1749\u20131756 (2023).","journal-title":"JAMA"},{"key":"50774_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/ijpp.12670","volume":"29","author":"YS Alsowaida","year":"2021","unstructured":"Alsowaida, Y. S., Almulhim, A. S., Oh, M., Erstad, B. & Abraham, I. Sensorineural hearing loss with macrolide antibiotics exposure: A meta-analysis of the association. Int. J. Pharm. Pract. 29, 21\u201328 (2021).","journal-title":"Int. J. Pharm. Pract."},{"key":"50774_CR17","doi-asserted-by":"publisher","first-page":"00786","DOI":"10.1183\/23120541.00786-2020","volume":"8","author":"E Henkle","year":"2022","unstructured":"Henkle, E. et al. Comparative safety of inhaled corticosteroids and macrolides in Medicare enrolees with bronchiectasis. ERJ Open Res. 8, 00786\u201302020 (2022).","journal-title":"ERJ Open Res."},{"key":"50774_CR18","first-page":"820","volume":"148","author":"K Dabekaussen","year":"2022","unstructured":"Dabekaussen, K. et al. Association of outpatient oral macrolide use with sensorineural hearing loss in children, adolescents, and young adults. JAMA Otolaryngol. Head Neck Surg. 148, 820\u2013827 (2022).","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"50774_CR19","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1093\/jac\/dkab232","volume":"76","author":"A Vanoverschelde","year":"2021","unstructured":"Vanoverschelde, A. et al. Macrolide-associated ototoxicity: A cross-sectional and longitudinal study to assess the association of macrolide use with tinnitus and hearing loss. J. Antimicrob. Chemother. 76, 2708\u20132716 (2021).","journal-title":"J. Antimicrob. Chemother."},{"key":"50774_CR20","doi-asserted-by":"publisher","first-page":"e0217951","DOI":"10.1371\/journal.pone.0217951","volume":"14","author":"M Tanaka","year":"2019","unstructured":"Tanaka, M. et al. Analysis of drug-induced hearing loss by using a spontaneous reporting system database. PLoS One 14, e0217951 (2019).","journal-title":"PLoS One"},{"key":"50774_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000380746","volume":"20","author":"N Vannson","year":"2015","unstructured":"Vannson, N. et al. Quality of life and auditory performance in adults with asymmetric hearing loss. Audiol. Neurootol. 20, 38\u201343 (2015).","journal-title":"Audiol. Neurootol."},{"key":"50774_CR22","doi-asserted-by":"publisher","first-page":"e0119616","DOI":"10.1371\/journal.pone.0119616","volume":"10","author":"P Dawes","year":"2015","unstructured":"Dawes, P. et al. Hearing loss and cognition: The role of hearing AIDS, social isolation and depression. PLoS One. 10, e0119616 (2015).","journal-title":"PLoS One."},{"key":"50774_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/CIA.S26059","volume":"7","author":"A Ciorba","year":"2012","unstructured":"Ciorba, A., Bianchini, C., Pelucchi, S. & Pastore, A. The impact of hearing loss on the quality of life of elderly adults. Clin. Interv. Aging 7, 159\u2013163 (2012).","journal-title":"Clin. Interv. Aging"},{"key":"50774_CR24","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/geront\/43.5.661","volume":"43","author":"DS Dalton","year":"2003","unstructured":"Dalton, D. S. et al. The impact of hearing loss on quality of life in older adults. Gerontologist 43, 661\u2013668 (2003).","journal-title":"Gerontologist"},{"key":"50774_CR25","doi-asserted-by":"publisher","DOI":"10.1159\/000530757","author":"K Kirubalingam","year":"2023","unstructured":"Kirubalingam, K. et al. Hearing loss and dementia: A population-based cohort study. Dement. Geriatr. Cogn. Disord. https:\/\/doi.org\/10.1159\/000530757 (2023).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"50774_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glad117","author":"JR Smith","year":"2023","unstructured":"Smith, J. R., Huang, A. R., Lin, F. R., Reed, N. S. & Deal, J. A. The population attributable fraction of dementia from audiometric hearing loss among a nationally representative sample of community-dwelling older adults. J. Gerontol. A Biol. Sci. Med. Sci. https:\/\/doi.org\/10.1093\/gerona\/glad117 (2023).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"50774_CR27","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 6, e1000097 (2009).","journal-title":"PLoS Med."},{"key":"50774_CR28","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup, D. F. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 283, 2008\u20132012 (2000).","journal-title":"JAMA."},{"key":"50774_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.21032\/jhis.2016.41.1.123","volume":"41","author":"SR Shim","year":"2016","unstructured":"Shim, S. R., Shin, I. S. & Bae, J. M. Intervention meta-analysis using STATA software. J. Health Info. Stat. 41, 123\u2013134 (2016).","journal-title":"J. Health Info. Stat."},{"key":"50774_CR30","doi-asserted-by":"publisher","first-page":"e2019008","DOI":"10.4178\/epih.e2019008","volume":"41","author":"SR Shim","year":"2019","unstructured":"Shim, S. R. & Kim, S. J. Intervention meta-analysis: Application and practice using R software. Epidemiol. Health. 41, e2019008 (2019).","journal-title":"Epidemiol. Health."},{"key":"50774_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1164","volume":"7","author":"AA Veroniki","year":"2016","unstructured":"Veroniki, A. A. et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res. Synth. Methods 7, 55\u201379 (2016).","journal-title":"Res. Synth. Methods"},{"key":"50774_CR32","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg, C. B. & Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088\u20131101 (1994).","journal-title":"Biometrics"},{"key":"50774_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/bmj.316.7124.61","volume":"316","author":"M Egger","year":"1998","unstructured":"Egger, M. & Smith, G. D. Bias in location and selection of studies. BMJ. 316, 61\u201366 (1998).","journal-title":"BMJ."},{"key":"50774_CR34","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne, J. A. C. et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 366, l4898 (2019).","journal-title":"BMJ."},{"key":"50774_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2288-14-45","volume":"14","author":"CKL Lo","year":"2014","unstructured":"Lo, C. K. L., Mertz, D. & Loeb, M. Newcastle-Ottawa Scale: Comparing reviewers\u2019 to authors\u2019 assessments. BMC Med. Res. Methodol. 14, 45 (2014).","journal-title":"BMC Med. Res. Methodol."},{"key":"50774_CR36","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1097\/MAO.0000000000001887","volume":"39","author":"A Alrwisan","year":"2018","unstructured":"Alrwisan, A., Antonelli, P. J., Brumback, B. A., Wei, Y. J. & Winterstein, A. G. Azithromycin and sensorineural hearing loss in adults: A retrospective cohort study. Otol. Neurotol. 39, 957\u2013963 (2018).","journal-title":"Otol. Neurotol."},{"key":"50774_CR37","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/lary.26190","volume":"127","author":"M Etminan","year":"2017","unstructured":"Etminan, M., Westerberg, B. D., Kozak, F. K., Guo, M. Y. & Carleton, B. C. Risk of sensorineural hearing loss with macrolide antibiotics: A nested case-control study. Laryngoscope 127, 229\u2013232 (2017).","journal-title":"Laryngoscope"},{"key":"50774_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/jac\/dkh519","volume":"55","author":"GW Amsden","year":"2005","unstructured":"Amsden, G. W. Anti-inflammatory effects of macrolides\u2013an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?. J. Antimicrob. Chemother. 55, 10\u201321 (2005).","journal-title":"J. Antimicrob. Chemother."},{"key":"50774_CR39","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00228-011-1161-x","volume":"68","author":"P Zarogoulidis","year":"2012","unstructured":"Zarogoulidis, P. et al. Macrolides: From in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur. J. Clin. Pharmacol. 68, 479\u2013503 (2012).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"50774_CR40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/00006454-199704000-00025","volume":"16","author":"JO Klein","year":"1997","unstructured":"Klein, J. O. History of macrolide use in pediatrics. Pediatr. Infect. Dis. J. 16, 427\u2013431 (1997).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"50774_CR41","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.idc.2009.06.013","volume":"23","author":"JM Zuckerman","year":"2009","unstructured":"Zuckerman, J. M., Qamar, F. & Bono, B. R. Macrolides, ketolides, and glycylcyclines: Azithromycin, clarithromycin, telithromycin, tigecycline. Infect. Dis. Clin. North Am. 23, 997\u20131026 (2009).","journal-title":"Infect. Dis. Clin. North Am."},{"key":"50774_CR42","doi-asserted-by":"publisher","first-page":"613","DOI":"10.4065\/74.6.613","volume":"74","author":"S Alvarez-Elcoro","year":"1999","unstructured":"Alvarez-Elcoro, S. & Enzler, M. J. The macrolides: Erythromycin, clarithromycin, and azithromycin. Mayo Clin. Proc. 74, 613\u2013634 (1999).","journal-title":"Mayo Clin. Proc."},{"key":"50774_CR43","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1099\/jmm.0.035568-0","volume":"61","author":"L Boyanova","year":"2012","unstructured":"Boyanova, L. et al. Numerous risk factors for Helicobacter pylori antibiotic resistance revealed by extended anamnesis: A Bulgarian study. J. Med. Microbiol. 61, 85\u201393 (2012).","journal-title":"J. Med. Microbiol."},{"key":"50774_CR44","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1128\/AAC.46.9.3020-3025.2002","volume":"46","author":"LK Ng","year":"2002","unstructured":"Ng, L. K., Martin, I., Liu, G. & Bryden, L. Mutation in 23S rRNA associated with macrolide resistance in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 46, 3020\u20133025 (2002).","journal-title":"Antimicrob. Agents Chemother."},{"key":"50774_CR45","doi-asserted-by":"publisher","first-page":"609","DOI":"10.4187\/respcare.05943","volume":"63","author":"AW Huckle","year":"2018","unstructured":"Huckle, A. W., Fairclough, L. C. & Todd, I. Prophylactic antibiotic use in COPD and the potential anti-inflammatory activities of antibiotics. Respir. Care 63, 609\u2013619 (2018).","journal-title":"Respir. Care"},{"key":"50774_CR46","doi-asserted-by":"publisher","first-page":"102095","DOI":"10.1016\/j.pupt.2021.102095","volume":"71","author":"J Pollock","year":"2021","unstructured":"Pollock, J. & Chalmers, J. D. The immunomodulatory effects of macrolide antibiotics in respiratory disease. Pulm. Pharmacol. Ther. 71, 102095 (2021).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"50774_CR47","first-page":"Cd002203","volume":"11","author":"KW Southern","year":"2012","unstructured":"Southern, K. W., Barker, P. M., Solis-Moya, A. & Patel, L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst. Rev. 11, Cd002203 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"50774_CR48","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12874-022-01550-8","volume":"22","author":"KL Grantham","year":"2022","unstructured":"Grantham, K. L., Kasza, J., Heritier, S., Carlin, J. B. & Forbes, A. B. Evaluating the performance of Bayesian and restricted maximum likelihood estimation for stepped wedge cluster randomized trials with a small number of clusters. BMC Med. Res. Methodol. 22, 112 (2022).","journal-title":"BMC Med. Res. Methodol."},{"key":"50774_CR49","doi-asserted-by":"publisher","first-page":"167","DOI":"10.5152\/iao.2022.21416","volume":"18","author":"L Franz","year":"2022","unstructured":"Franz, L. et al. Ototoxicity of immunosuppressant drugs: A systematic review. J. Int. Adv. Otol. 18, 167\u2013176 (2022).","journal-title":"J. Int. Adv. Otol."},{"key":"50774_CR50","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.amjmed.2007.02.004","volume":"120","author":"DB Goldstein","year":"2007","unstructured":"Goldstein, D. B., Need, A. C., Singh, R. & Sisodiya, S. M. Potential genetic causes of heterogeneity of treatment effects. Am. J. Med. 120, S21\u2013S25 (2007).","journal-title":"Am. J. Med."},{"key":"50774_CR51","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41576-020-00297-6","volume":"22","author":"AJ Kwok","year":"2021","unstructured":"Kwok, A. J., Mentzer, A. & Knight, J. C. Host genetics and infectious disease: New tools, insights and translational opportunities. Nat. Rev. Genet. 22, 137\u2013153 (2021).","journal-title":"Nat. Rev. Genet."},{"key":"50774_CR52","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/bs.apha.2018.03.002","volume":"83","author":"O Osanlou","year":"2018","unstructured":"Osanlou, O., Pirmohamed, M. & Daly, A. K. Pharmacogenetics of adverse drug reactions. Adv. Pharmacol. 83, 155\u2013190 (2018).","journal-title":"Adv. Pharmacol."},{"key":"50774_CR53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2174\/187152912801823138","volume":"12","author":"F Scarpini","year":"2012","unstructured":"Scarpini, F., Cappellone, R., Auteri, A. & Puccetti, L. Role of genetic factors in statins side-effects. Cardiovasc. Hematol. Disord. Drug Targets 12, 35\u201343 (2012).","journal-title":"Cardiovasc. Hematol. Disord. Drug Targets"},{"key":"50774_CR54","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/154411130401500104","volume":"15","author":"LA Torpet","year":"2004","unstructured":"Torpet, L. A., Kragelund, C., Reibel, J. & Nauntofte, B. Oral adverse drug reactions to cardiovascular drugs. Crit. Rev. Oral Biol. Med. 15, 28\u201346 (2004).","journal-title":"Crit. Rev. Oral Biol. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50774-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50774-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50774-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T08:14:29Z","timestamp":1704183269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50774-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["50774"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-50774-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"20 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}